Sarcopenia in the Acute Stroke (SARCOSTROKE)

November 26, 2025 updated by: Centre Hospitalier Régional d'Orléans

Follow up of Strength and Body Composition With Impedancemeter Device During the First 10 Days After Acute Stroke.

Regardless of the cause of immobilization, within days or weeks there is rapidly a decrease in strength and muscle mass, which can lead to sarcopenia. In severe strokes, immobilization and neurologic damage may be added to promote sarcopenia. Several studies in Asian populations confirm rapid increases in sarcopenia rates after stroke, but there are only rare data in Western populations. The aim of this work is to monitor during the first 10 days after a severe stroke leading to a reduction in ambulation, the evolution of muscle strength (studied in dynamometry), body composition (studied by impedance measurement) and sarcopenia rates. Investigators will also look for factors that predict the occurrence of this sarcopenia (such as sex, age, initial deficiency, stroke volume, swallowing disorders, etc.).

Study Overview

Status

Terminated

Conditions

Intervention / Treatment

Detailed Description

In stroke patients, muscle damage combines many mechanisms such as immobilization, nutritional disorders , sympathetic activity, inflammation and denervation . These general factors explain that post-stroke sarcopenia is also observed on the side considered healthy .

Several meta-analyzes have been carried out on this subject . In the study by Inoue et al., which brings together 35 studies on the subject, the rates of sarcopenia observed were overall of the order of 15% before the stroke, of 30% in the 10 days post-stroke and of the order of 50% in the first semester . Only about 10 studies have been performed in the acute phase . However, the majority of these studies were performed in Asian populations (32 of them). But this is a population with demographic and physiological characteristics that are different from those in the West. Thus, body mass indices are lower and the representation of older people is higher in the population (the Japanese population is the oldest in the world).

Body composition may be a predictor of the course of recovery from stroke. In a cohort study it was thus shown by bioimpedance measurements that patients with the lowest muscle mass index had more severe neurological deficits at admission. They also had poorer functioning and longer hospital stays. Muscle mass is an independent variable in predicting what happens to people who have had a stroke.

Strokes cause motor deficits that reduce movement on the deficit side but also on the unaffected side. Sarcopenia (loss of strength and muscle mass) develops in the first few days after a stroke and worsens the consequences of neurologic damage. While immobilization rapidly leads to sarcopenia, sarcopenia has been poorly studied in acute stroke, especially in Asian populations, which are unrepresentative of Western populations.

The aims of this work are to:

  1. Longitudinally determine rates of sarcopenia in the acute phase of stroke during follow-up over the first 10 days after stroke.
  2. Determine the factors that predict the occurrence of sarcopenia (age, degree of initial deficiency, lesion volume, etc.)
  3. Track body composition by segment (4 limbs and trunk) over time in impedance measurement, particularly by distinguishing between deficit and nondeficit. Investigators will distinguish the usual parameters (skeletal muscle mass, angle phase).
  4. Monitor motor recovery of the deficient upper limb and determine whether muscle mass is a prognostic factor for recovery.

Measurement will be done at three time (T1, T2, T3) T1 corresponds to the first 72 hours post stroke T2 corresponds at 5 days (+/-1 days) T2 corresponds at 8 days (+/-1 days)

Study Type

Interventional

Enrollment (Actual)

6

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
      • Orléans, France, 45067
        • CHU d'Orléans

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Acute stroke patient
  • Over 18 years of age
  • Functional Ambulation Categories (FAC) < 3
  • NIHSS upper limb score ≥ 1
  • Able to understand assessment instructions
  • Non-objection to the study
  • Affiliated with a social security scheme

Exclusion Criteria:

  • Person under guardianship or curatorship.
  • Person deprived of liberty
  • Person under court protection
  • Other neurological or rheumatological pathology limiting mobility
  • Presence of a pacemaker or defibrillator.
  • Pregnant or breast-feeding woman

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: Impedance measurement for acute stroke patient
Acute stroke patients will benefit from impedance measurement and dynamometry to determine the evolution of sarcopenia rates.
Diagnostic test: Bioimpedancemetry

2. Bioimpedancemetry at T1, T2, T3 ; the measurement will be

  1. Squeletic mass (total and for each of the 4 limbs)
  2. Angle phase (total and for each of the 4 limbs)
Other: Dynamometry
Dynamometry will be performed to assess the strength of each upper limb (deficient and non deficient) at T1, T2, T3

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
rate of sarcopenia
Time Frame: Day 1
The rate of sarcopenia will be defined using the maximum flexion force of the fingers measured on a digital Jamar dynamometer in the healthy upper limb.
Day 1
rate of sarcopenia
Time Frame: Day 1
The rate of sarcopenia will be define using appendicular muscle mass index (Kg/m2) measured by impedancemetry
Day 1
rate of sarcopenia
Time Frame: Day 5
The rate of sarcopenia will be defined using the maximum flexion force of the fingers measured on a digital Jamar dynamometer in the healthy upper limb.
Day 5
rate of sarcopenia
Time Frame: Day 5
The rate of sarcopenia will be define using appendicular muscle mass index (Kg/m2) measured by impedancemetry
Day 5
rate of sarcopenia
Time Frame: Day 8
The rate of sarcopenia will be defined using the maximum flexion force of the fingers measured on a digital Jamar dynamometer in the healthy upper limb.
Day 8
rate of sarcopenia
Time Frame: Day 8
The rate of sarcopenia will be define using appendicular muscle mass index (Kg/m2) measured by impedancemetry
Day 8

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
total skeletal muscle mass and per limb segment
Time Frame: Day 5
total skeletal muscle mass and per limb segment (expressed in kg)
Day 5
total skeletal muscle mass and per limb segment
Time Frame: Day 8
total skeletal muscle mass and per limb segment (expressed in kg)
Day 8
total angle phase and per limb segment
Time Frame: Day 5
total angle phase and per limb segment expressed in degrees and evaluated at a frequency of 50kHz
Day 5
total angle phase and per limb segment
Time Frame: Day 8
total angle phase and per limb segment expressed in degrees and evaluated at a frequency of 50kHz
Day 8
Muscular strength of the upper limb deficiency
Time Frame: Day 1
Muscular strength of the upper limb deficiency expressed in Kg
Day 1
Muscular strength of the upper limb deficiency
Time Frame: Day 5
Muscular strength of the upper limb deficiency expressed in Kg
Day 5
Muscular strength of the upper limb deficiency
Time Frame: Day 8
Muscular strength of the upper limb deficiency expressed in Kg
Day 8

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Centre Hospitalier Régional d'Orléans

Investigators

  • Principal Investigator: Canan OZSANCAK, PH, CHU Orléans

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 28, 2024

Primary Completion (Actual)

August 6, 2024

Study Completion (Actual)

August 6, 2024

Study Registration Dates

First Submitted

August 16, 2024

First Submitted That Met QC Criteria

September 16, 2024

First Posted (Actual)

September 19, 2024

Study Record Updates

Last Update Posted (Estimated)

December 4, 2025

Last Update Submitted That Met QC Criteria

November 26, 2025

Last Verified

November 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CHUO-2023-10

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Stroke, Acute

Clinical Trials on Bioimpedancemetry

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bahrain

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe